About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
PMID: 33661711 Journal: PEDIATRIC HEMATOLOGY AND ONCOLOGY Year: 2021 Reference: Pediatr Hematol Oncol. 2021 May;38(4):331-345. doi: 10.1080/08880018.2020.1868637. Epub 2021 Mar 4. Impact factor: 1.969 Publication type: Paper in international publication Authors: Mozo, Yasmina, Bueno, David, Sisinni, Luisa, Fernandez-Arroyo, Alba, Rosich, Blanca, Martinez, Antonio Perez, Uria, Maria Luz, Heredia, Cristina Diaz de, Mestre-Duran, Carmen, Pascual, Cristina Ferreras Barbara et al. DOI: 10.1080/08880018.2020.1868637
PMID: 33277309 Journal: Cancer Discovery Year: 2021 Reference: Cancer Discov. 2021 Mar;11(3):545-559. doi: 10.1158/2159-8290.CD-20-0779. Epub 2020 Dec 4. Impact factor: 39.397 Publication type: Review in international publication Authors: Laetsch, Theodore W, DuBois, Steven G, Bender, Julia Glade, Macy, Margaret E, Moreno, Lucas et al. DOI: 10.1158/2159-8290.CD-20-0779
PMID: 33613322 Journal: Frontiers in Physiology Year: 2021 Reference: Front Physiol. 2021 Feb 5;12:628236. doi: 10.3389/fphys.2021.628236. eCollection 2021. Impact factor: 4.566 Publication type: Paper in international publication Authors: Rizzuto, Valeria, Koopmann, Tamara T, Blanco-Alvarez, Adoracion, Tazon-Vega, Barbara, Idrizovic, Amira, Diaz de Heredia, Cristina, Del Orbe, Rafael, Pampliega, Miriam Vara, Velasco, Pablo, Santen, Gijs W E et al. DOI: 10.3389/fphys.2021.628236
PMID: 33602686 Journal: CLINICAL CANCER RESEARCH Year: 2021 Reference: Clin Cancer Res. 2021 May 1;27(9):2515-2522. doi: 10.1158/1078-0432.CCR-20-3677. Epub 2021 Feb 18. Impact factor: 12.531 Publication type: Paper in international publication Authors: Kudo, Toshihiro, Kagawa, Yoshinori, Fernandez, Elena Elez, Garcia-Foncillas, Jesus, Bando, Hideaki, Taniguchi, Hiroya, Vivancos, Ana, Akagi, Kiwamu, Garcia, Ariadna, Denda, Tadamichi et al. DOI: 10.1158/1078-0432.CCR-20-3677
PMID: 32107177 Journal: ANALES DE PEDIATRIA Year: 2020 Reference: An Pediatr (Barc). 2020 Jul;93(1):59.e1-59.e10. doi: 10.1016/j.anpedi.2019.12.014. Epub 2020 Feb 24. Impact factor: 1.313 Publication type: Paper in national publication Authors: Mirones, Isabel, Moreno, Lucas, Patino-Garcia, Ana, Toribio, Maria Luisa, van Santen, Hisse M, Menendez, Pablo, Perez-Martinez, Antonio, Garcia-Castro, Javier, Blanquer, Miguel, Sanchez-Salinas, Andres et al. DOI: 10.1016/j.anpedi.2019.12.014
PMID: 32080355 Journal: BONE MARROW TRANSPLANTATION Year: 2020 Reference: Bone Marrow Transplant. 2020 Jun;55(6):1214. doi: 10.1038/s41409-020-0838-0. Impact factor: 4.725 Publication type: Letter or abstract Authors: Boenig, Halvard, Nava, Tiago, Ansari, Marc, Dalle, Jean-Hugues, de Heredia, Christina Diaz, Gungor, Tayfun, Trigoso, Eugenia, Falkenberg, Ulrike, Bertaina, Alice, Gibson, Brenda et al. DOI: 10.1038/s41409-020-0838-0
PMID: 32029909 Journal: BONE MARROW TRANSPLANTATION Year: 2020 Reference: Bone Marrow Transplant. 2020 Jun;55(6):1126-1136. doi: 10.1038/s41409-020-0818-4. Epub 2020 Feb 6. Impact factor: 4.725 Publication type: Paper in international publication Authors: Kuhlen, Michaela, Matic, Toni, Buchner, Jochen, Kalwak, Krzysztof, Lawitschka, Anita, Yesilipek, Akif, Lucchini, Giovanna, Peters, Christina, Turkiewicz, Dominik, Niinimaki, Riitta et al. DOI: 10.1038/s41409-020-0818-4
PMID: 32007712 Journal: EUROPEAN JOURNAL OF CANCER Year: 2020 Reference: Eur J Cancer. 2020 Mar;127:123-129. doi: 10.1016/j.ejca.2019.12.021. Epub 2020 Jan 30. Impact factor: 7.275 Publication type: Paper in international publication Authors: Orbach, Daniel, van Noesel, Max M, Corradini, Nadege, Minard-Colin, Veronique, Zanetti, Ilaria, Bisogno, Gianni, Gallego, Soledad, Merks, Johannes H M, De Salvo, Gian Luca, Ferrari, Andrea et al. DOI: 10.1016/j.ejca.2019.12.021
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).
Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.
